Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 118 of 144 pages ‹ First < 116 117 118 119 120 > Last ›
HSL2382
Hall TS.
Reimagining the learned intermediary rule for the new pharmaceutical marketplace.
Seton Hall Law Rev 2004; 35:(1):193-261
HSL2383
Miller M, Supranowicz P, Targowski M, Piechowiak-Modrzejewska E.
[Evaluation of quality and accessibility of health education materials. I. The opinion of health personnel]
Rocz Panstw Zakl Hig. 2004; 55:(2):115-23
HSL2384
Parojcic D.
[Patent medicines and its advertising in Serbia during the second half of the 19th and first half of the 20th century]
Rev Hist Pharm (Paris). 2004; 52:(342):229-46
HSL2397
Green CJ, Kazanjian A, Helmer D.
Informing, advising, or persuading? An assessment of bone mineral density testing information from consumer health websites
Int J Technol Assess Health Care. 2004 Spring;20(2): 2004 Spr; 20:(2):156-66
HSL3680
Anonymous .
Merck & co invents new syndromedinformation deprivation.
Scrip. 2004; 2983:5
HSL3688
Canadian Institute for Health Information.
Drug expenditure in Canada 1985 to 2003.
Ottawa: Canadian Institute for Health Information. 2004
http://www.cihi.ca.
HSL3753
Meyer U.
[Pharmaceutical industry and "New German Medicine" ("Neue Deutsche Heilkunde")]
Med Ges Gesch 2004; 23:165-82
HSL3776
Srivastava R, Chandra A, Kumar G.
Strategic imperatives for globalization of industries in developing countries: an Indian pharmaceutical industry example.
Health Mark Q 2004; 22:(1):57-69
HSL3777
Tengilimoglu D, Kisa A, Ekiyor A.
The pharmaceutical sales rep/physician relationship in Turkey: ethical issues in an international context.
Health Mark Q 2004; 22:(1):21-39
HSL3778
Tengilimoglu D, Korkmaz S, Akinci F, Parsons AL.
Managerial implications of medical sales representative perceptions of job duties, job qualifications, and other performance-related issues.
Health Mark Q 2004; 22:(2):3-26
HSL3803
Puska P, Lehtomaki P, Eckstein H, Juvonen H.
[Sources of medicine for developing countries].
Duodecim 2004; 120:(23):2833-40
HSL4760
Tett SE.
A perspective on Australia's National Medicines Policy.
Can J Clin Pharmacol 2004 Spr; 11:(1):e28-38
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=5025&uid=15226524&db=PubMed&url=http://www.cjcp.ca/pdf/Australia_National_MedicinesDEMO.pdf
HSL4846
[No authors listed].
Ethical code of the pharmaceutical industry in Slovakia. (Excerpts).
Med Etika Bioet 2004 Aut; 11:(3-4):11-22
HSL5308
American Academy of Pain Medicine Council on Ethics
AAPM Ethics Charter
: American Academy of Pain Medicine Council on Ethics 2004
http://www.painmed.org/productpub/pdfs/EthicsCharter.pdf
HSL5328
Dunning D, Heath C, Suls JM.
Flawed self-assessment: implications for education and the workplace.
Psychol Sci Public Interest 2004; 5:69-106
HSL5371
Poon EG, Blumenthal D, Jaggi T, Honour MM, Bates DW, Kaushal R.
Overcoming barriers to adopting and implementing computerized physician order entry systems in U.S Hospitals
Health Aff. 2004; 23:184-190
http://content.healthaffairs.org/cgi/content/full/23/4/184
HSL19334
Stell LK.
Two cheers for physicians' conflicts of interest.
Mt Sinai J Med 2004; 71:(4):236-42
http://www.ncbi.nlm.nih.gov/pubmed/15365589
HSL5781
Foote M.
Guidelines and policies for medical writers in the biotech industry: an update on the controversy.
Biotechnol Annu Rev 2004; 10:259-64:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7CTS-4DN8YX3-7&_coverDate=12%2F31%2F2004&_alid=431466823&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=18058&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=867f3a71a0241a0bf5b894eb3c7bdec4
HSL19380
Hemminki E, Karttunen T, Hovi SL, Karro H.
The drug industry and medical practice--the case of menopausal hormone therapy in Estonia.
Soc Sci Med 2004; 58:(1):89-97
http://linkinghub.elsevier.com/retrieve/pii/S0277953603001503
HSL7323
Chi J.
Should PBMs disclose their contracts? - Here are pros, cons
Drug-Top (Drug-Topics) 2004; 148:(10):52
HSL7325
Bronstein D, Frei R.
Debate heats up on drug reimportation
Pharmacy-Practice-News 2004; 31:(4):
HSL7326
Minnesota governor's Web site promotes cut-rate Canadian rxs
Pharmacy Times 2004; 70:(40):10
HSL7327
Berry D.
N.C. halts illegal prescription businesses
Pharmacy-Today 2004; 10:(3):43
HSL7328
FDA wants ad changes
Pharmacy Times 2004; 70:(4):
HSL7330
Zwillich T.
Drugmakers vow to hold election-year ground in Rx pricing
Drug Topics 2004; 148:(4):74
HSL7332
Vitry A.
Is Australia free from direct-to-consumer advertising?
Australian Prescriber 2004; 27:(1):4-6
HSL7336
Medicines Australia code of conduct: breaches
Australian Prescriber 2004; 27:(1):6-8
HSL7337
Holmes ER, Desselle SP.
Evaluating the balance of persuasive and informative content within product-specific print direct-to-consumer ads
Drug Information Journal 2004; 38:(1):83-98
HSL7338
Kayne S.
Alzheimers patients get a cheap deal
New Zealand Pharmacy 2004; 24:(2):17
HSL8827
Goozner M.
The $800 Million Pill: The Truth behind the Cost of New Drugs
Berkeley, CA: University of California Press 2004
http://www.ucpress.edu/books/pages/10083.html
HSL8828
Le Carre J.
The Constant Gardener : A Novel
: Scribner/Simon & Schuster 2004
http://www.simonsays.com/content/book.cfm?tab=1&pid=427053
HSL8829
Angell M.
The Truth About the Drug Companies: How They Deceive Us and What to Do About It
New York: Random House 2004
http://www.randomhouse.com/acmart/?view=about
HSL8830
Avorn J.
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs
New York: Random House 2004
http://www.randomhouse.com/catalog/display.pperl?isbn=9780375414831
HSL9047
Daemmrich A
Pharmacopolitics: Drug Regulation in the US and Germany
Chapel Hill, NC: Univ North Carolina Press 2004
http://uncpress.unc.edu/books/T-7301.html
HSL9673
Wang LN.
Challenges of medicines for children
Pharmaceutical Journal 2004; 272:(7301):680
HSL9674
Kayne S.
Opportunity knocks in animal health
Pharmaceutical Journal 2004; 272:(7300):647
HSL9675
Lumb J.
Students are better than they think at conducting home medication reviews
Pharmaceutical Journal 2004; 272:(7300):644
HSL9676
Wang LN.
New ways to ensure patient loyalty
Pharmaceutical Journal 2004; 272:(7300):635-636
HSL9677
Lancet concludes that OTC statins are not the answer
Pharmaceutical Journal 2004; 272:(7300):632
HSL9679
Aronson JK.
Medication errors resulting from the confusion of drug names
Expert Opinion on Drug Safety 2004; 3:(3):167-172
HSL9684
Wilce H.
Temazepam capsules: What was the problem?
Australian Prescriber 2004; 27:(3):58-59
HSL9685
Watson MC, Bond CM.
The evidence-based supply of non-prescription medicines: Barriers and beliefs
International Journal of Pharmacy Practice 2004; 12:(2):65-72
HSL9688
York A.
Thinking inside the box
Lancet Oncology 2004; 5:(6):332
HSL9689
Cholesterol agents lead all therapeutic classes in prescription drug sales
Drug Benefit Trends 2004; 16:(5):232-233
HSL9690
Nash DB.
Outpatient drug safety: The final frontier
P and T 2004; 29:(5):
HSL9692
Adverts broke MHRA rules
Pharmaceutical Journal 2004; 272:(7298):564
HSL9696
650 million prescriptions dispensed in England last year
Pharmaceutical Journal 2004; 272:(7297):533
HSL9697
Dickson M.
Key factors in the rising cost of new drug discovery and development
Nature Reviews Drug Discovery 2004; 3:(5):417-429
HSL9698
Calcitonin intranasal - Unigene: Salcatonin intranasal - Unigene
Drugs in R and D 2004; 5:(2):90-93
HSL9699
Patient group directions
MeReC Briefing 2004; (23):6-8
HSL9700
Supplementary prescribing
MeReC Briefing 2004; (23):1-6
HSL9701
Wechsler J.
McClellan moves to block counterfeits and require barcodes before leaving FDA
Pharmaceutical Technology Europe 2004; 16:(4):17-21
HSL9702
Wechsler J.
Electronic information systems promote. Drug development and patient safety
Pharmaceutical Technology Europe 2004; 16:(2):20-24
HSL9705
Blenkinsopp J.
Out of the dispensary and into the pharmacy - POM-to-P switching
Pharmaceutical Journal 2004; 272:(7296):508-509
HSL9706
Approval for OTC statins
Pharmaceutical Journal 2004; 272:(7296):497
HSL9707
Viagra "reward card" introduced in the US
Pharmaceutical Journal 2004; 272:(7296):496
HSL9708
Part and parcel of change
Pharmaceutical Journal 2004; 272:(7296):494
HSL9709
Motions for branch representatives' meeting
Pharmaceutical Journal 2004; 272:(7295):487-490
HSL9710
Plan to allow prison officers to supply medicines
Pharmaceutical Journal 2004; 272:(7295):466
HSL9713
Baeyens AJ.
Impact of the European Clinical Trials Directive on academic clinical research.
Med Law 2004; 23:(1):103-10
HSL9714
Grubb D.
Promotion of over-the-counter medicines [8]
Australian Prescriber 2004; 27:(2):33
HSL9715
Fusier I, Freville C, Tollier C, Husson MC.
Heterogeneous information on drug interactions: Review by a drug database editor for health practitioners
Journal de Pharmacie Clinique 2004; 23:(1):25-30
HSL9716
Giraud C, Galene E, Begue D, Tixier C, Clement P.
Use and adverse events of nitrous oxide/oxygen 50/50 mol/mol analgesic mixture: Assessment of cohort temporary authorisation results of SOL France pharmaceutical establishment
Journal de Pharmacie Clinique 2004; 23:(1):5-18
HSL9717
MHRA publicises changes to misleading advertisements
Pharmaceutical Journal 2004; 272:(7294):440
HSL9719
Onohwosafe PS, Olaseha IO.
Factors influencing self-modication among students of Abadina College, Ibadan, Nigeria
International Journal of Health Promotion and Education 2004; 42:(1):27-32
HSL9720
Minhas R.
OTC statins: The implications for primary prevention in the UK
British Journal of Cardiology 2004; 11:(2):89-91
HSL9721
Peterson GM.
Risk factors - but only after excluding high-risk subjects
Pharmacoepidemiology and Drug Safety 2004; 13:(4):253
http://www3.interscience.wiley.com/cgi-bin/abstract/106600330/ABSTRACT?SRETRY=0
HSL9722
Willy ME, Li Z.
What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling
Pharmacoepidemiology and Drug Safety 2004; 13:(4):201-206
http://www3.interscience.wiley.com/cgi-bin/abstract/104530108/ABSTRACT
HSL9725
Improving systems should help to reduce errors due to look-alike and sound-alike drug names
Drugs and Therapy Perspectives 2004; 20:(4):23-26
HSL9727
Pharmacy software with remote supervision capability launched
Pharmaceutical Journal 2004; 272:(7293):405
HSL9728
Research and development costs: The great illusion. Response to Prescrire
Prescrire International 2004; 13:(70):77-79
HSL9729
Industrial interests versus public health: The gap is growing
Prescrire International 2004; 13:(70):71-76
HSL9730
Bubbles burst..
Prescrire International 2004; 13:(70):70
HSL9731
No sartans during pregnancy
Prescrire International 2004; 13:59
HSL9732
Nifuroxazide: New restrictions in children
Prescrire International 2004; 13:(70):53
HSL9733
Why remove old but still valuable drugs?
Prescrire International 2004; 13:(70):42
HSL9734
O'Connell B.
Medicare Reform and Health Savings Accounts: A Trojan Horse for Industry?
BioPharm International 2004; 17:(4):24-26
HSL9736
Kumwenda L.
OTC products should be supplied in child resistant containers
Pharmaceutical Journal 2004; 272:(7291):348
HSL9737
Lipitor is top seller worldwide
Pharmaceutical Journal 2004; 272:(7291):344
HSL9739
Nash DB.
Follow-ups
P and T 2004; 29:(3):
HSL9741
Kirby J.
Pharmacists must not overlook the opportunities on offer in animal health
Pharmaceutical Journal 2004; 272:(7290):321-322
HSL9742
Cairns A.
Veterinary medicines - A challenge for the pharmacy profession to meet
Pharmaceutical Journal 2004; 272:(7290):320
HSL9743
Alam MM.
We should give manufacturers the benefit of the doubt [10]
Pharmaceutical Journal 2004; 272:(7289):281
HSL9744
Astbury FG, Mahaffy PJ.
Managing the risk of thalidomide (multiple letters)
Pharmaceutical Journal 2004; 272:(7289):278-279
HSL9745
Kirby PM.
Back to the dark ages
Pharmaceutical Journal 2004; 272:(7287):215
HSL9746
Pfizer helps pharmacists capitalise on health care market
Pharmaceutical Journal 2004; 272:(7287):209
HSL9752
Wechsler J.
Pharmaceutical Pricing and Healthcare Access: Lead Policy Agenda
Pharmaceutical Technology 2004; 28:(3):26-34
HSL9754
Government looks at instalment dispensing for benzodiazepines
Pharmaceutical Journal 2004; 272:(7288):238
HSL9755
Harris KM, Devries A, Dimidjian K.
Trends in Naltrexone Use among Members of a Large Private Health Plan
Psychiatric Services 2004; 55:(3):221
HSL9756
Tawab M.
Viagra from the Internet
Pharmazeutische Zeitung 2004; 149:(9):43
HSL9757
Hollon MF.
Direct-to-consumer marketing of prescription drugs: a current perspective for neurologists and psychiatrists.
CNS Drugs 2004; 18:(2):69-77
HSL9758
Thomson D, Capstick T.
How a risk management programme can ensure safety in thalidomide use
Pharmaceutical Journal 2004; 272:(7286):190-191
HSL9760
Valaitis J, Peterson T.
Ethical Dilemmas: Scenario 3
Wisconsin Medical Journal 2004; 103:(1):11-12
HSL9761
Bellingham C.
How to improve contraception services
Pharmaceutical Journal 2004; 272:(7285):149-150
HSL9762
Patients should be able to buy Tamiflu, according to NPA
Pharmaceutical Journal 2004; 272:(7285):146
HSL9764
Foran TM.
Choices in hormonal contraception
Medicine Today 2004; 5:(2):30-37
HSL9765
Goldenberg MM.
Medicare and the New Generic Drug Legislation
P and T 2004; 29:(2):89-94
HSL9767
Parvez N, Ahmed T, Monif T, Saha N, Sharma PL.
Comparative bioavailability of three oral formulations of sustained release theophylline in healthy human subjects
Indian Journal of Pharmacology 2004; 36:(1):29-33
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=36&issue=1&spage=29
HSL9769
Law and ethics bulletin
Pharmaceutical-Journal 2004; 272:(7282):70
HSL9770
Medicine adverts appeals process clarified
Pharmaceutical Journal 2004; 272:(7282):48
Page 118 of 144 pages ‹ First < 116 117 118 119 120 > Last ›
